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A HISTORICAL REVIEW OF THE
ACCOUNTING TREATMENT OF
RESEARCH AND DEVELOPMENT COSTS
Abstract: This study reviews the literature and the practice of accounting for research and development (R&D) costs from the first
reference in 1917 to the current treatment. The conceptual treatment
of R&D is compared to current financial accounting rules and explanation of the evolution of the current rules is presented. The economic and social consequences of the current rules which require
R&D costs to be expressed are examined. The paper explores possible
alternative treatment of R&D costs. As a contrast to U.S. practice, the
accounting treatment of R&D costs in other countries is discussed.
Given the findings of this paper, a strong case can be made for
changing the way that R&D costs are accounted for in the United
States.
In today's rapidly changing world which relies increasingly
on technology, the investments made in research and development ( R & D ) are more critical than ever to the economic future
of companies and countries. The current financial accounting
for R & D costs in the United States is to expense these costs as
incurred. 1 W h i l e this accounting treatment is certainly question1 Attempts have been made by authors such as Higgins (1954) to distinguish
between research costs and development costs:
Development costs are usually thought of as being the costs of
attempting to convert the results of research to a commercial basis.
Since the terms "research" and "development" are often used interchangeably, it is important to distinguish between the two. Research in industry today is usually used in connection with products currently being produced or with new products and is commonly termed "general research." It includes the study of the suitability of materials for specific purposes, the experimental testing
of material, the study of manufacturing processes, and techniques
and similar research work.
Unless otherwise indicated, which is frequently done, R&D costs are considered as a single cost in this paper. Development costs are frequently referred to
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able from a theory standpoint, the expense-as-incurred rule may
have a practical consequence of being a disincentive to firms
making R&D expenditures. Arguably, as a consequence, the current accounting treatment may hinder the United States' economic position in the global marketplace.
In this paper, the history of accounting for research and
development costs is analyzed to determine why the current
accounting rules require immediate expensing. Thus, the evolution of accounting rules is traced from 1917 to the present. The
reporting environment, issues and investigation conducted by
the FASB in 1974 which led to the expense-as-incurred rule is
examined. Particularly significant to the thesis of this paper is
empirical evidence that was available at the time to counter the
FASB's overly pessimistic assessment of the likely outcome of
an R&D expenditure. The paper then reviews the more recent
pronouncement about accounting for software development
costs as a contrast to R&D accounting. Finally the paper examines how other countries account for R&D costs as another contrast to the U.S. practice, despite the similarity to the U.S. accounting problem. Before tracing the historical evolution of the
accounting for research and development costs, the paper examines the importance of R&D and the importance of how R&D
costs are accounted for in the next section of the paper.
OVERVIEW OF THE R&D ISSUE
Clearly, R&D costs are necessary for the survival of many
businesses and are the "engine that drives our economy." Solow
[1957] estimated that 90 percent of the per capita increase in
output between 1909 and 1949 was caused by technological
change. Furthermore, the Committee for Economic Development [Denison, 1962] estimated 36 percent of the increase in
output per worker between 1929 and 1957 was caused by research and development, and only 9 percent by capital intensity.
Technology is even more pivotal in today's world economy.
Thus, the amount of R&D expenditures and how these expendi-

as "applied research" while research with no immediate application is referred
to as "pure research." As is the practice in the United States, the following
generally do not fall under the definition of accounting for R&D costs: research
under contract for others, physical plant for research activities, and costs incurred in the extractive industries.
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tures are accounted have important economic impact on the
future.
In an unpublished study of 182 research intensive corporations, 62 percent of the respondents spent from 25 percent to
350 percent of profits in R&D costs [Nix, 1972]. Unfortunately,
the rate at which U.S. companies are increasing their R&D efforts is declining: "[a] wave of corporate restructuring and a
continuing emphasis on short-term profits are pushing R&D
spending back into the doldrums of the mid-1970s" [R&D
Scoreboard, 1988]. According to the National Science Foundation, the first real decline in R&D expenditures in the past fourteen years occurred in 1989 [Tax Foundation, 1990]. The Industrial Research Institute's Annual R&D Trends Survey indicates
that 1992 will see a slowdown in the growth of industrial R&D
in the United States [November, 1991].
A major Japanese competitive trade advantage over the U.S.
is Japan's heavy emphasis on the process-applied area of R&D
while utilizing advanced technology from the West [Mansfield,
1988]. Although this emphasis on process-applied R&D is not
likely to change in the near future, Japanese firms now seem to
devote about the same percentage of their R&D budget to risky
long-term projects as American firms [Mansfield, 1988]. This
differs significantly from the early 1970s when Japanese industrial R&D was largely characterized by low-risk and short-term
projects [Peck and Tamura, 1976]. Thus, the Japanese are increasingly moving into long-term R&D as the means for creating future innovative products and securing a long-term trade
advantage. U.S. firms may be reluctant to invest in long-term
R&D because of the expense-as-incurred financial reporting
rules. Yet "[corporations in the U.S.A. are beginning to realize
the intellectual property may be their most valuable asset in
competing with Japan" [Dreyfuss, 1987].
The theoretical foundation for the current requirement of
expensing R&D costs as incurred certainly may be questioned.
The accounting model with the annual measurement of income
may be best suited for an agrarian economy characterized by
manual labor and a static technology. However, income may
not be as easily or exactly measured in an industrialized
economy characterized by long-lived capital assets and a rapidly
changing technology. A longer time perspective then the annual
accounting measurement cycle may be required to measure performance of many companies which sell technology based products.
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In regard to the financial treatment of R&D costs, current
practice may be defective in the following respects: (1) matching
of revenue and associated costs often is not achieved, (2) R&D
is a major asset but may not be presented as such, and (3)
disclosure of R&D costs has not kept pace with its increasing
importance. In short, methods used in accounting for R&D
costs may not present a realistic picture of economic consequences of the firm's research and operating activities.
Accounting income is estimated by matching expenses and
revenues over the appropriate time period with cost allocation
being essential to the matching process. In a rapidly changing
technology, however, the useful lives of capital assets become
inordinately difficult to estimate. Technology may render a
plant obsolete many years before it wears out. The lives of many
assets are determined by technological change. Therefore, cost
allocation to determine annual profits becomes even more difficult, yet more important, given a rapidly changing technology.
If capital assets are currently expensed, this allocation distorts
present income even more than capitalization [Thomas, 1969].
Imagine expensing a multimillion dollar plant during construction. Current accounting rules for R&D costs have the same
effect because intangible assets arising from research costs are
expensed in the year they are incurred. As Bierman and Dukes
conclude, "[t]he result of expensing R&D may distort corporate
decision making and lead to faulty measurement of income and
changes in income through time. Business firms do not generally begin new product or process development projects until
the principal technical uncertainties have been resolved"
[Bierman and Dukes, 1975].
A study of 200 companies on the Fortune 500 list suggested
that new ventures need, on average, eight years before they
reach profitability [Biggadike, 1979]. Therefore, it may be that
many R&D expenditures fit the FASB definition of an asset, like
expenditures for capital equipment which are required to be
capitalized. This is to say that R&D expenditures are made with
the expectation of future benefits and are subject to reasonable
measurement. Because R&D costs are incurred to secure future
benefits, expenditures for R&D costs should be capitalized as
assets and allocated to expense in the periods in which they
help generate revenues.
If one accepts the hypothesis that capital markets are efficient in the procuring of information, "[d]isclosure of the
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amount of research and development expenditures is an extremely important first step" [Bierman and Dukes, 1975]. As
suggested by Drebin [1966], either cost-allocation procedures or
current market values are preferable to expensing-as-incurred
for reporting R&D costs.
In support of capitalization of R&D costs and the matching
principle, though the timing of benefits from R&D costs is uncertain, an appropriate allocation arguably is better than an immediate write-off. A subjective estimate of the value is better
than an arbitrary write-off to no value [Drebin, 1966]. However,
for such subjective estimates to be an improvement, a considerable amount of attention would have to be given in the development of industry guidelines. An analysis into what type(s) of
R&D should be capitalized and at what stage of completion
R&D should be capitalized would be necessary. Such efforts
could result in a much better matching of these costs and related revenue. Other researchers indicate that the current expense treatment for R&D costs may be in conflict with the
matching principle of financial reporting [Bierman and Dukes,
1975].
Historically, the accounting for R&D costs has ranged from
requiring that all R&D costs be expensed in the year incurred
(generally the current practice in the United States) to that of
deferring and thereby allocating and matching R&D costs to the
periods to which they help generate revenue. Although tax considerations should not be allowed to dictate accounting theory,
the income tax aspects of accounting for R&D have had an impact on the choice of methods used to expense R&D costs. Prior
to 1954, tax law required that the deduction of R&D costs conform to the timing of the reported expense in the financial statements. Therefore, by immediately expensing R&D costs in the
period incurred, the corporation received an immediate writeoff for tax purposes [Raby, 1964]. After 1954, corporations
could get an immediate tax deduction for R&D expenditures
whether expensed or capitalized for financial reporting purposes. Despite the ability to get the deduction irrespective of
accounting treatment, after 1954 most companies continued the
practice of expensing R&D costs for accounting purposes.
Although the choice of methods in financial reporting of
R&D costs is no longer allowed, there seems to be little complaint from management that R&D costs ought to be capitalized
and amortized, rather than expensed. The apparent satisfaction
of management with the current accounting rule of "expense-as-
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incurred" may be due to the fear that if financial accounting
rules allow or require capitalization of R&D costs, the tax rules
might be changed and the immediate write-off for tax purposes
may be lost. The lack of groundswell support by management
for changing the accounting for R&D costs may also be due to
concerns over the problem that could be created if capitalized
R&D costs suddenly must be written-off because the research
proved unproductive, and, as a result, a large loss occurred.
Managers also seem to be concerned that capitalizing R&D
costs may complicate consolidated reporting, especially when
entities with capitalized R&D costs are acquired or disposed.
The satisfaction of corporate management with the expensing of
R&D costs may also be due to the rule giving management the
ability "to manage income" of a given accounting period by cut
ting or accelerating R&D expenditures. Finally, the current
practice of expensing R&D costs may be preferred by management because managers feel that the company currently has the
freedom to extensively disclose (or alternatively not to extensively disclose) in the notes to the financial statements the information that management wants to convey to the investor about
R&D activities.
Given this background about R&D, the problem with the
current accounting treatment and the apparent lack of demand
for change, the history of accounting for R&D costs is traced in
the sections that follow. Exhibit I contains a historical overview
of the major events in R&D accounting. These events are discussed in detail in the sections that follow.
THE HISTORICAL RECORD (1917 TO PRESENT)
A search of accounting literature reveals no reference to
accounting for R&D costs prior to 1917. However, in 1917 the
Federal Reserve Board [Federal Reserve Bulletin, 1917] accepted
R&D as a deferred charge in published financial statements.
The Federal Reserve Board reaffirmed this position in 1929
[Federal Reserve Bulletin, 1929].
At approximately the same time other institutions, such as
the National Association of Cost Accountants, promoted the
same deferral treatment. In the 1924 edition of the National
Association of Cost Accountant's Bulletin, the following statement is found:
It is perfectly proper to carry (the cost of developing a
new article or line) as a deferred account, and an esti-
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Exhibit I
A Historical S u m m a r y of the Financial
A c c o u n t i n g f o r R & D in the U n i t e d States
1917
1924
1926
1929
19201930s
1954
Prior
to 1954
1954
1960s
1964
1972
1975
1985
1985 to
Present

Federal Reserve Board — Deferral supported.
NACA — Deferral supported.
NACA — Deferral reaffirmed.
Federal Reserve Board — Deferral reaffirmed.
IRS — Deferral preferred.
AICPA — Deferral supported only if there is a reasonable connection
to future operations.
Tax law allowed expenditures to be expensed only when the same
procedure was followed in the financial statements.
Tax legislation allows direct write-off regardless of the financial accounting treatment.
Gellein — Disclosure varies considerably.
Raby — Majority of companies expense as incurred because of established practice prior to 1954 tax legislation.
APB No. 22 and SEC No. 125 — Mandatory disclosure in the financial statements and annual 10K report.
SFAS No. 2 (1974) — Direct write-off mandated. Disclosure required.
Expenditures defined.
SFAS No. 86 — Later capitalization and subsequent write-off allowed on computer software expenditures with proven feasibility.
Direct write-off required. Later capitalization and subsequent writeoff allowed on computer software expenditures with proven feasibility. Disclosure varies considerably.

mate should be m a d e to ascertain the number of units
o r volume of sale o r units, as well as an estimate of the
length of time over which this development will b e
spread [1924].
But,
. . . experimenting (covering the current or minor experimenting that is continual in most manufacturing
establishments) should b e charged against current operations each month as the money is expended and assessed against the lines of products affected [1924].
In 1926, the National Association of Cost Accountants again
stated that it w a s acceptable to capitalize the cost of developing
a n e w product (to defer R & D expenses) " . . . if you are starting
out with a n e w product in which you have a very definite knowl-
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edge that there is a field for it, and you are going to spend a lot
of money, and you know it is going to come back to you"
[1926]. At its 1954 annual meeting, the American Institute of
Certified Public Accountants supported the deferral treatment
only if future benefits were definite: "Development expenses
should be deferred only in those cases where they have a reasonable connection with future operations" [Higgins, 1954].
Thus, accounting organizations had generally supported the deferral treatment for research and development expenditures. It
may be seen, however, that the definition of what could be deferred became, over time, more conservative and restrictive.
Paton [1955] supported the deferral treatment in an accounting
text:
On the other hand, whenever research and related costs
are incurred in substantial amount on a particular
project which is expected to result in a valuable new
process, perhaps patentable, there is much to be said
for deferring followed by systematic absorption in later
years.
Perhaps the most influential institution affecting the accounting treatment of research and development costs has been
the Internal Revenue Service. The Internal Revenue Service tax
policy in the 1920s and 1930s favored the deferral treatment of
research and development costs. From the beginning, early tax
court decisions and accounting literature supported research
and development cost deferral; but scientists and economists
supported immediate deduction for tax purposes as a means to
stimulate research and development.
Businessmen, constantly on the alert for immediate benefits, increased political pressure on Congress to allow the immediate deduction of R&D costs for tax purposes. However, the
tax law prior to 1954 allowed the current expensing of research
and development only when the same procedure was followed
in the financial statement. Thus, before 1954, business firms
may have switched from deferral to current expensing of research and development in published financial statements to
take advantage of the tax benefits of immediate deduction.
In 1954, Congress passed tax legislation which allowed for
the immediate deduction of R&D costs as they were incurred;
these deductions could be taken irrespective of the financial accounting treatment of these costs. Thus there was no longer a
tax requirement that R&D costs be treated for tax purposes ac-
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cording to the treatment on the financial statements. Interestingly, in 1954 Congress merely removed the tax-financial accounting conformity requirement. Congress still permitted the
taxpayer to elect to capitalize and amortize R&D costs for tax
purposes or to deduct these costs as incurred. This tax election
for R&D costs continues today.
The following quotation from the Senate Finance Committee
Report on the Internal Revenue Code of 1954 illustrates the intent of Congress in making the tax law change:
No specific treatment is authorized by present law for
research and experimental expenditures. To the extent
that they are ordinary and necessary they are deductible; to the extent that they are capital in nature they
are to be capitalized and amortized over useful life.
Losses are permitted where amounts have been capitalized in connection with abandoned projects, and recovery through amortization is provided where useful life
of these capital items is determinable, as in the case of
a patent. However, where projects are not abandoned
and where a useful life cannot definitely be determined,
taxpayers have had no means of amortizing research
expenditures.
To eliminate uncertainly and to encourage taxpayers to
carry on research and experimentation the House and
your Committee's bill provide that these expenditures,
incurred subsequent to December 31, 1953, may, at the
option of the taxpayer, be treated as deductible expenses. It also provides that a taxpayer may elect to
capitalize such expenditures and if no other means of
amortization is provided, may write them off over a
period of not less than 60 months, beginning with the
month in which benefits are first realized. [Higgins,
1954].
Raby logically asserts that the majority of companies were
probably currently expensing research and development in the
mid-sixties because of income tax law prior to 1954. "Perhaps a
major force underlying this accounting treatment is that before
1954 what was done in the books and financial statements controlled what was allowed to be done on tax returns" [Raby, August 1964]. Furthermore, once this practice was established, it
was continued regardless of the post-1954 tax impact. Raby [August 1964] states, "[a]s a consequence, companies quite logically
set up [the] practice of expensing research expenditures, and
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this practice has continued since, even though tax justification
for doing so has ceased to exist."
Indeed, a survey of 244 companies in the 1960s [Gellein and
Newman, 1973] disclosed that the common practice was to currently expense research and development expenditures. The investigation also revealed 60 percent of the companies disclosed
the dollar amount of research and development in some way,
but only 10 percent disclosed the accounting treatment in published financial statements. Therefore, comparability of financial statements was difficult.
Acceptance of the current expense treatment for research
and development expenditures in accounting practice is revealed in the accounting literature. Braithwaite [1967] said in
an article in Accountancy, "The [British] auditor . . . will take a
jaundiced attitude to any attempt to capitalize research expenditures on the grounds of expected future benefits to the company." Thus, auditors were most comfortable when research
and development costs were expensed; but Braithwaite stated
further, "[t]he auditor . . . may agree that in the long run a
research program necessarily must be judged by its overall fruitfulness." The contradiction in Braithwaite's statements about
current expensing of research and development and future benefits from research and development is obvious.
Auditors have an incentive to support the immediate writeoff of research and development expenditures to avoid unnecessary audit risk. Prior to the SFAS No. 2 [1974] expense requirement, business firms had (and still have) an incentive to capitalize research costs having little future benefit so current earnings
would be more impressive. When it became apparent to the
auditor and to others that these costs had no future benefit,
they were written off. If the write-off caused sharp reduction in
profits and investors saw their investments decline in value, the
auditor might face investor liability suits for being a party to
misleading prior financial statements. Thus, much of the support for expensing R&D costs as incurred came from auditors
who otherwise might face difficulty in evaluating R&D costs.
Prior to SFAS No. 2 [1974], four basic questions regarding
the official accounting treatment of R&D in financial statements
remained unanswered: (1) What activities should be included in
R&D? (2) What portion, if any, of the costs related to these R&D
activities should be deferred? (3) How should these deferred
costs be amortized? (4) How should R&D be disclosed in the
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financial statements? These unanswered questions made the
comparability of R&D information between companies and, for
a company, between years very difficult. Also, these questions
made current and future financial accounting for R&D very difficult.
Prior to SFAS No. 2, R&D expenditures were sometimes
classified as separate expenses on the income statement. Some
companies included R&D expenses with other expenses, yet
other companies included R&D in the cost of goods sold. Also,
management had the flexibility of either currently expensing
R&D or capitalizing R&D and writing it off over future time
periods. Large write-offs of capitalized R&D costs would occur
unexpectedly when it became apparent that the expenditures no
longer had a future benefit. The variety of accounting treatments of R&D costs led to criticism over the lack of uniform
accounting.
Because of criticism over the variety of methods of accounting for R&D, action was taken by the Accounting Principles
Board (APB) and the Securities and Exchange Commission
(SEC) in 1972. The APB Opinion No. 22 [1972] made the disclosure of R&D expenditures in financial statements mandatory.
Also, the SEC required the reporting of R&D in the Annual 10-K
Report. Although badly needed, the disclosure requirements of
the APB and the SEC did not solve the problem of the "proper"
accounting treatment for R&D costs in financial reporting.
However, these disclosures made apparent to financial statement users the significance of R&D expenditures in relationship
to accounting measurements.
A BRIEF SUMMARY AND CRITIQUE OF SFAS NO. 2,
ACCOUNTING FOR RESEARCH AND DEVELOPMENT COSTS
As of January 1975, the Financial Accounting Standards
Board (FASB) required the expensing of all R&D expenditures
during the year incurred. The two exceptions to this rule are (1)
R&D under contract for others, and (2) plant and equipment
(an R&D lab) which has alternative future uses. A further exception was made by the SFAS No. 86 [1985] for the capitalization
of computer software for which technological feasibility has
been established.
In SFAS No. 2, FASB recognized the problems associated
with the accounting for R&D costs. However, the FASB did an
inadequate amount of research on the problem before making
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its decision in 1974: "[t]he FASB did not undertake a major
research effort for the project. The FASB staff interviewed a
limited number of selected financial analysts and commercial
bankers and reviewed a substantial number of published financial statements" [SFAS No. 2, Para. 20, 1974]. Consequently, the
effect of the current expense treatment on the total dollar
amount of R&D was not carefully considered. Thus, the now
established practice of currently expensing R&D costs may not
be appropriate for all investments or business firms. The current expense-as-incurred practice may well have reduced R&D
costs in total and caused a shift from "pure" to "applied" R&D.
The need to maintain current reported profits and earnings per
share may have resulted in a change in type and amount of
R&D expenditures.
The major objectives of the Statement were (1) to provide
more uniformity in accounting reporting for R&D; and (2) to
provide useful financial information about R&D. FASB Statement No. 2 defines R&D activities, identifies costs associated
with these activities, and specifies the accounting treatment and
disclosure of these costs. It specifically excludes certain activities found only in the extractive industries, but includes R&D in
other industries.
In Statement No. 2, FASB discussed four alternatives in
accounting for R&D. These four alternatives are:
1. Charge all costs to expense when incurred;
2. Capitalize all costs when incurred;
3. Capitalize costs when incurred if specified conditions are fulfilled and charge all other costs to expense;
4. Accumulate all costs in a special category until the
existence of future benefits can be determined [SFAS
No. 2, 1974].
Accounting theory supports alternative three, which is to:
. . . capitalize costs when incurred if specified conditions are fulfilled and charge all other costs to expense"
[SFAS No. 2, 1974]. Consequently, when research and
development expenditures are expected to benefit future time periods, they should be capitalized and amortized over the periods benefited. This capitalization and
future write-off is consistent with the matching concept
as defined by the Financial Accounting Standards
Board. The pronouncement refers to matching as,
"identifying, measuring, and relating revenues and ex-
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penses of an enterprise for an accounting period"
[FASB, 1974].
However, the FASB still chose the first alternative which is,
. . charge all costs to expense when incurred" [1974]. As support for this decision, the FASB utilized research studies that
emphasized a high failure rate for R&D. For example,
one study of a number of industries found that an average of
less than 2 percent of new product development projects were
commercially successful" [Higgins, 1954]. Another study estimated exceedingly high new product failure rates, ranging from
30 to 90 percent. In all likelihood, these studies were not and
are not representative of typical research and development
projects. Other studies indicated more optimistic results.
Mansfield [May, 1972] found more than 75 percent of the
projects he examined had estimated probabilities of success of
80 percent or greater. Forty-four percent of these projects were
technically successful, and only 16 percent were technically unsuccessful. Scherer [1970] attributes this high success ratio to
the fact that ". . . business firms do not, as a rule, begin new
product or process development until the principle technical
difficulties have been whittled down through inexpensive research, conducted either by their own personnel or by outsiders." Thus, R&D success is much higher than inferred in the
Board's decision.
The FASB [1974] also states, " . . . a direct relationship between R&D and specific future revenue generally has not been
demonstrated." However, as previously stated, many projects
are successful and future revenue is directly related to them.
Numerous studies [Minasian, May 1969] have been undertaken
to show this relationship; they have had some success in linking
R&D activity with future revenue amounts, even though the
studies encountered data problems. Most of these studies use
the number of patents or number of employees as statistical
data, rather than the dollar value spent on R&D. Additional
study of the outcomes of research, with actual R&D expenditure
data, may prove enlightening to accounting rule makers.
The FASB [1974] indicated, ". . . at the time most R&D
costs are incurred, the future benefits are, at the most, uncertain." This statement implies there is no economic resource creation. If no future benefits are generated, it would certainly be
irrational for a firm to undertake an R&D project. However,
many studies show the marginal rate of return on R&D is either
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comparable to or greater than investment return on the capital
expenditures. Denison [1962] calculated the rate of return on
R&D to be about the same as for plant and equipment expenditures, but he assumed no time lag. The return rate for R&D
investment would have been much greater with a time lag.
Grilich [1964] found the rate of return for investment in agricultural research to be between 35 and 170 percent. More specifically, Mansfield [May 1972] estimates the marginal rate of return on R&D in the petroleum industry to be over 40 percent,
while in the chemical industry, Minasian [May 1969] estimates
a 50 percent marginal rate of return on R&D.
Referring to the total economy, Fellner [1970] estimates the
rate of return on R&D to be in excess of 18 percent. Assuming a
static technology, 18 percent is much greater than the marginal
rate of return from plant and equipment. Consequently, contrary to the FASB opinion, there was tangible evidence of resource generation at the time of the R&D expenditure. Perhaps
a final irony can be found in the following statement from the
FASB. R&D should not be capitalized even when future benefits
are known simply because they " . . . cannot be measured with a
reasonable degree of accuracy . . ." [SFAS No. 2, 1974]. Following this reasoning, fixed assets, such as plant and equipment,
would not be capitalized because the future productivity of
fixed assets is subject to uncertain marketing conditions and
rapid technology change. Who can estimate accurately the business life of fixed assets? For example, nuclear power plants may
be closed on a moment's notice. Under the same rationale,
"goodwill" in a purchase of a business would never be shown
on the balance sheet and the intangible drilling cost of a "wildcat" oil well, whether "wet" or "dry" can never be an asset. Thus,
in comparison to other costs that are capitalized, R&D costs do
not seem to be of any greater uncertainty or risk.
Given the reasoning behind the FASB's decision, it may be
concluded that SFAS No. 2 had, at best, a questionable theoretical foundation in support for its treatment of R&D costs.
THE HISTORICAL RECORD FOLLOWING THE
1974 ENACTMENT OF SFAS NO. 2
A considerable amount of financial accounting research
was conducted subsequent to the 1974 issuance of SFAS No. 2
to determine the impact, if any, of the expense-as-incurred requirement on R&D expenditures. A central thrust of this re-
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search concerned whether the expense-as-incurred rule might
result in decreased corporate spending on R&D in order to
maintain profit levels.
The contradictory findings of much of this research were
published in a special supplement to the 1980 Journal of Accounting Research. Horwitz and Kolodny [1980] concluded that
the rule did, in some cases, reduce R&D expenditure. "We conclude that the evidence supports the premise that the expense
only rule caused a relative decline in R&D outlays for small high
technology firms which had primarily used the deferred method
of measurement."
Other researchers such as Dukes, Dyckman and Elliott
[1980] concluded that SFAS No. 2 did not have any effect on
R&D expenditures: "all three sets of tests fail to support an effect on research and development expenditures attributable to
SFAS No. 2." Wolfson [1980] notes that Horwitz and Kolodny
provided " . . . no evidence of market inefficiencies occurring as
a result of SFAS No. 2." Vigeland [1981] reports that ". . . no
market reaction was observed." In other words, lacking evidence
to the contrary, we must conclude investors are aware of the
impact of SFAS No. 2 on reported earnings. This suggests that
the price of a company's stock would not decrease in response
to the effect of SFAS No. 2 on reported earnings, and the company would not be motivated to reduce R&D expenditures as a
result of the rule.
Most researchers would probably agree that we do not understand the R&D decision making process. Authors such as
Ball [1980] state there is an almost complete absence of theory
on the determination of R&D expenditure and accounting
policy choice. Marshall [1980] states, "[t]he process of determining R&D expenditures, including the choice and role of accounting method is so complex that designs such as those used by
Dukes, et. al., and Horwitz and Kolodny are incapable of producing creditable results." If nothing else, the research of the
late 1970s has forced us to acknowledge we may draw no firm
conclusions in regard to the impact of SFAS No. 2 on R&D
expenditures.
Although additional research was conducted in the 1980s
regarding the impact of SFAS No. 2, few, if any, conclusive findings were made. In 1984, Elliott, Richardson, Dyckman and
Dukes attempted to reconcile the results of the 1980 Horwitz
and Kolodny study with their study [1980] which did not show a
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SFAS No. 2 effect. The results of the 1984 study were again
inconclusive. Interestingly, this study did show a relative decline
in R&D expenditures prior to the 1974 issuance of SFAS No. 2.
Elliott, Richardson, Dyckman and Duke [1984] suggest that we
cannot conclude that SFAS No. 2 caused changes in R&D expenditures. In a 1984 investigation of managers' adoptions to
SFAS No. 2, Selto and Clouse also found inconclusive results in
regard to the effect of the FASB mandated expensing of R&D
requirement. However, Daley and Vigeland [1983] observed that
" . . . R&D capitalizing firms were more highly levered, employed
more public debt, and had a higher ratio of dividends to unrestricted retained earnings, and were smaller in size than R&D
expensing firms." This finding hints that the FASB requirement
had an economic impact on these smaller R&D firms.
A 1987 study of R&D management and corporate financial
policy by Guerard, Bean and Andrews analyzed the relationship
of R&D investment, dividends and new debt financing decisions. Not surprisingly, they found significant relationships
among these variables. They concluded that changes in these
variables occurred simultaneously and could not be considered
independently. In regard to the effect of SFAS No. 2, the efficient market hypothesis that stock prices reported the impact of
R&D expenditures whether they were capitalized or not was
neither confirmed nor denied.
Horwitz and Normolle examined the effect that SFAS No. 2
had on small technology firms in securing R&D awards from
federal agencies [1989]. The study explored whether the detrimental effect of the expense-as-incurred requirement on small
firms' financial ratios might make the firms ineligible for governmental R&D contracts. As a result of SFAS No. 2, the financial ratios of these companies were negatively affected, but no
evidence was found that the expensing requirement reduced the
amount of R&D awards by federal agencies to small research
intensive companies.
DISCLOSURE OF RESEARCH AND DEVELOPMENT
EXPENDITURES CURRENT PRACTICE
Disclosure of R&D expenditures is, today, not unlike that
existing prior to 1975 when SFAS No. 2 was implemented. Corporations, in their annual reports, display a wide variety of information regarding R&D expenditures. Some companies provide no disclosure, others offer considerable detail. The annual
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dollar amount of R&D by year is often separately disclosed on
comparative income statements. Occasionally, either in the
notes or in management's discussion of corporate activities, information is provided for R&D such as percentage of operating
revenue, percentage change from the previous year, number of
full-time R&D employees, and directions the R&D effort is taking. It appears that management of these companies disclose
what they want with regard to the firm's R&D activities.
Although companies are required to expense R&D costs in
the year incurred, there is still considerable latitude in what
management discloses to investors. It seems that companies in
which R&D activities reflect favorably upon them take ample
opportunity to disclose such; other companies for various reasons provide little or no information regarding their R&D efforts. Thus, irrespective of the required current expensing of
R&D, stockholders are frequently not well informed about R&D
efforts.
A BRIEF SUMMARY AND CRITIQUE OF SFAS NO. 86
ACCOUNTING FOR THE COSTS OF COMPUTER SOFTWARE
TO BE SOLD, LEASED OR OTHERWISE MARKETED
The costs of developing computer software that is to be
marketed are similar to R&D costs. In both cases, the costs are
mainly salaries of personnel who are engaged in the projects.
Software development costs and R&D costs are also somewhat
similar as to uncertainty of outcomes, (risks and revenue
amounts) and as to long periods of time between expenditures
and sales. Given these similarities, it is interesting to note the
contrast in accounting for the costs related to developing computer software of software vendors to costs of R&D of a drug
manufacturer, biotechnology firm or even to the R&D costs of a
computer hardware manufacturer.
Before the issuance of SFAS No. 86 in 1985, the financial
statements of computer software companies provided inadequate disclosure about software development costs, and comparisons between companies in the industry were hampered by
the variety of accounting practices for software development
costs. Thus, the latter problem was very similar to the R&D cost
situation prior to SFAS No. 2, while the former problem is still
unresolved with regard to R&D today.
SFAS No. 86 [1985] addressed the issue of whether software
producers should expense development costs as they are in-

Published by eGrove, 1992

17

Accounting Historians Journal, Vol. 19 [1992], Iss. 1, Art. 3

68

The Accounting Historians Journal, June 1992

curred or capitalize them on the theory that the cost is creating
a productive asset. The potential impact of this issue is reflected
in the fact that the computer software industry spent $7 billion
in 1985 [Chakravarty and Kolseka]. SFAS No. 86 requires software producers to expense development costs while the product
is still in the R&D phase; but as soon as the product is "technologically feasible," companies must capitalize any further development costs and amortize them over the life of the product,
The practical problem in applying this statement is determining
at what point in time a product becomes technologically feasible. This is particularly a complex problem in the case of computer software which is often redesigned.
SFAS No. 86's treatment of software development costs follows the conceptual definition of an asset in financial accounting: an asset is a cost which benefits a future accounting period.
However, the Statement did not resolve the problem of the lack
of inter-company comparability of financial statements. For instance, in 1984 IBM capitalized 67 percent of its investment in
software products while other companies reported capitalizing
between 3 to 25 percent of their software development costs
[Chakravarty and Koselka]. Thus it appears that SFAS No. 86
may not accomplish its intended purposes of providing better
disclosure and making software companies' financial statements
more comparable. The practical effect of the statement was to
allow software companies to determine when a product's asset
life begins. The software firm must make this critical accounting decision to determine what costs to capitalize for each software development project. As a result, there is still difficulty in
comparing companies within the industry from their financial
statements.
The experience with capitalization of software development
costs is instructive if changes to the accounting for R&D costs
are ever considered. Even though being more conceptually correct, the capitalization of R&D costs will not automatically produce pragmatic improvement. Indeed, less comparability between companies financial statements could result. If capitalization of R&D costs became the financial accounting rule, there
would probably be a requirement that a project reach "technological feasibility" before costs could be capitalized. Again, like
the experience with software development costs, such a vague
rule causes a wide range of interpretations and could cause the
problem of lack of comparability of financial statements be-
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tween R&D firms as well. Thus it is important, if changes to the
accounting for R&D are made to allow capitalization of costs,
that classification criteria be set forth as well to specify precisely when capitalization would begin in an R&D project.
THE HISTORICAL RECORD OF FINANCIAL ACCOUNTING
FOR R&D COSTS IN OTHER SELECTED COUNTRIES
In other English-speaking nations, i.e., Australia, Canada,
Great Britain, Ireland, etc., the capitalization of at least some
R&D costs is permitted. This practice usually has caused a
myriad of problems in defining research development and various types of research such as pure research versus applied. As
with the "technologically feasible" U.S. requirement for software
development costs, these distinctions are important to determine which costs are capitalized from those that are expensed.
As with the U.S. software costs, interpreting the rules and applying the distinctions can vary from company to company. Thus,
accounting for R&D costs, even within one country, can vary
considerably. As will be examined in this section, there is great
variation and problems with the accounting treatment around
the globe.
In 1983, the Australian accounting profession issued the
standard "Accounting for Research and Development Costs"
(AAS No. 13). The objectives of the standard were similar to
those of SFAS No. 2 issued in 1974: to provide useful information regarding R&D costs and to reduce the number of alternative accounting practices for R&D expenditures [Carnegie and
Turner, 1983].
Attempts were made in AAS No. 13 to distinguish between
research and development costs and between basic and applied
research. The definitions, not surprisingly, were difficult to
work with as observed in the following passage taken from AAS
No. 13:
4(a) Research means planned investigation undertaken
with the hope of gaining new scientific or technical
knowledge and understanding which will be useful in
developing a new product or service (hereinafter product), or a new process or technique (hereinafter process), or in bringing about a significant improvement to
an existing product or process.
4(b) Development means the translation of research
findings or other knowledge into a plan or design for a
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new product or process or for a significant improvement to an existing product or process.
AAS No. 13 further divided research into basic research and
applied research. Basic research was defined as ". . . original
investigation directed primarily towards the advancement of
knowledge," while applied research was defined as
. . original
investigation directed primarily towards solving recognized
practical problems." This distinction was made to assist the
practitioner in evaluating the classification of specific costs.
From these definitions, it appears distinguishing between development costs and applied research costs is an enigmatic chore.
AAS No. 13 allows "selective capitalization" in accounting
for R&D costs; that is, some R&D costs may be capitalized or
expensed in the period incurred while others must be currently
expensed. In general, both applied research and development
costs could be capitalized. Basic or pure research is required to
be expensed in the period incurred. Although the theory behind
AAS No. 13 is sound, the practical difficulties in defining and
distinguishing between research costs (pure and applied) and
development costs limit the usefulness of the approach.
In Canada, there is a very basic difference between Canadian and United States' accounting rules for R&D costs; in
Canada development costs should be deferred to future periods
if all of the following criteria are satisfied:
(a) the product or process is clearly defined and the
costs attributable thereto can be identified;
(b) the technical feasibility of the product or process
has been established;
(c) the management of the enterprise has indicated its
intention to produce and market, or use, the product or process;
(d) the future market for the product or process is
clearly defined or, if it is to be used internally
rather than sold, its usefulness to the enterprise has
been established; and
(e) adequate resources exist, or are expected to be
available, to complete the project. (CICA Handbook,
Aug. 1978).
By contrast, development costs in the United States must be
expensed in the period incurred.
In Great Britain, the accounting profession has taken the
position that both pure and applied research should be expensed in the period incurred [SSAP No. 13 revised, Jan. 1989].
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However, the British Accounting rules distinguish the development of new products and services from pure and applied research; these development costs, under certain circumstances,
should be deferred. It is the authors' opinion these distinctions
(which possess the same difficulties as those used in Australia)
are very difficult to define and utilize.
The reasoning behind the British requirements of expensing
pure and applied research is that these costs are regarded as
part of continuing operations required to maintain a company's
competitive position. Therefore, these costs cannot be placed on
the balance sheet as assets, but should be expensed in the period incurred. Also required is a significant amount of disclosure about the R&D activities of the period. If development
costs meet the rigid criteria specified in SSAP No. 13, they are
defined as intangible assets for balance sheet purposes and are
amortized as expense in revenue generation or written off immediately if found to be worthless.
The International Accounting Standards Committee takes
the position that research and development costs should usually
be charged to expense in the period in which they are incurred
[1980]. However, notes the Committee, ". . . if it can be demonstrated that the product or process is technically and commercially feasible and that the enterprise has adequate resources to
enable the product or process to be marketed—it may be appropriate to defer the costs of development activities to future periods."
It can be seen that the United States and other nations
share the difficulty of accounting for R&D costs. Despite problems of implementation and lack of comparability of financial
statements in some cases, other nations are more sophisticated
in distinguishing between types and stages of R&D. These countries specify accounting treatment according to the type of R&D
costs. Perhaps, U.S. accounting should consider adopting some
of the approaches used in these countries.
SUMMARY
Since research and development expenditures are significant in amount, the historical accounting treatment of this important cost was investigated. Historical research reveals that
accounting organizations, the Internal Revenue Service, and accounting practice originally supported capitalization and future
amortization of R&D expenditures. However, economic and so-
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cial forces exerted pressure for immediate write-off of R&D
costs because of the income tax advantage.
The Internal Revenue Service yielded to these forces but
required that R&D costs be currently expensed in published financial statements when immediate write-off for tax purposes
was to be allowed. This tax requirement was reversed in 1954,
but the current expensing technique had already become institutionalized into financial accounting.
Auditors who examined published financial statements supported the established practice of currently expensing research
and development costs. The difficulty in measuring future benefits of the expenditures and the lack of tangible, physical evidence were the main reasons given for this support. Also, management was reluctant to adopt accounting treatment that could
result in an unexpected immediate write-off of R&D "assets"
when deemed to have no future value.
In 1974, the FASB issued Statement No. 2 which required
that private research and development expenditures be currently expensed. The troublesome problem of whether to capitalize or to expense R&D costs was temporarily solved. No more
would the write-offs of past capitalized R&D costs cause drastic
declines in current income and in the stock price.
SFAS No. 2 was pragmatically designed to temporarily
handle the current problem of a lack of uniformity between
companies in accounting for R&D costs. Uniformity in the accounting for R&D costs was established by simply requiring all
firms to expense R&D in the year incurred. Thus, unlike the
treatment of other types of costs, R&D costs are arbitrarily expensed despite the fact that R&D meets the classic definition of
an asset for the "future benefit" inherent in such expenditures.
Also, apparently little analysis was undertaken by the FASB either to consider the success rate of R&D expenditures or to
consider the effect established practice would have on the dollar
amount and on the type of private research and development in
the United States. Nor was a close analysis undertaken by the
Board to determine to what extent research and development
might become a function of current profits as a result of the
current expense treatment. In accounting research conducted
since the issuance of SFAS No. 2 the impact of the requirement
to immediately expense R&D costs on the amount of R&D expenditures has been inconclusive. However, pressure is building
for more adequate disclosure of R&D costs and toward some
change in U.S. accounting rules to allow the capitalization of
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some costs as permitted in numerous foreign nations and,
within the U.S., as permitted for software development costs.
CONCLUSIONS AND IMPLICATIONS
FOR FURTHER RESEARCH
In more and more industries, research and development is
becoming the dominant asset. The accounting rules have not
kept pace with adequately disclosing and capitalizing this cost.
It is in both the investor's interest (in terms of rational decision
making) and the accounting profession's (in terms of responsibility to society and reputation) to reconsider the accounting for
R&D costs on the financial statements and the amount of detail
disclosed in notes to the statements.
Corporate reporting of R&D can be improved in two ways:
by disclosing more information about R&D spending and activities and by recognizing probable successful development expenditures as an asset that will give future benefits. The difficulties
encountered in determining at what point in time R&D costs
become an asset must be adequately addressed. This has not yet
been done. By contrast, in spite of the difficulties encountered
with SFAS No. 86, accounting rules do allow software development costs to be capitalized at some point in the development.
Arguably, accounting should afford R&D costs similar treatment.
In contrast to the United States, a number of foreign nations allow the deferment of at least some R&D costs, although
many definitional problems of research, pure research, applied
research, and development costs are encountered.
More research is needed in the classification of R&D costs.
Fortunately, a current study by the AICPA's Accounting Standards Executive Committee concerning the classification, capitalization and amortization of advertising costs clearly has implications for the accounting treatment of R&D costs [Flesher,
1979; also, Thompson, Hoskins, and Flesher, 1991]. This is especially true because advertising costs may be even more difficult to match with future revenue. Both R&D and advertising
costs are "intangible" in nature, are material in amount and
benefit future time periods. The expensing of either of these
costs in the period incurred frequently violates the matching
principle of accounting and distorts reported net income.
Flesher explores the " . . . possibility of integrating qualitative
marketing department information with that of accounting."
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Similar research which integrates qualitative R&D department
information with that of accounting may be appropriate. Also, a
comprehensive study of foreign countries' economic treatment
of R&D costs may be useful.
One financial accounting alternative for R&D costs currently being investigated is to classify R&D costs as a contra
stockholders' equity account when incurred rather than expensing in the period incurred. This approach would eliminate the
problem of calling R&D costs an asset and also would eliminate
the negative effect on current net income presently experienced
from expensing R&D costs when incurred. Another approach to
be considered would be the capitalization of R&D costs in an
account similar to organization costs and written off over a definite future time period regardless of revenue generation and
recognition.
Alternatively, accounting rule makers also should consider
expensing general research costs and capitalization of those
costs related to specific projects. These capitalized costs could
be then matched with the future revenue of the project, unless
the project's revenues prove too small to recover these capitalized costs which would lead to the write-off of the remaining
capitalized costs of the project [Milburn, 1968]. Milburn defines
general research as ". . . research of indirect benefit to the future and its contribution cannot be related to specific future
periods on a reasonable basis . . . and . . . specific development,
if successful, as identifiable with specific future benefits."
Milburn cites as support for his view APB No. 11, paragraph
14d, Accounting for Income Taxes, which follows:
Costs identifiable with future revenue or otherwise
identifiable with future time periods should be deferred
to those future periods. When a cost cannot be related
to future revenues or to future periods on some basis
other than revenues, or it cannot reasonably be expected to be recovered from future revenues, it becomes, by necessity, a cost or an expense of the current
period (or in some cases of a prior period).
The impact of SFAS No. 86, (accounting for the costs of
computer software) on R&D expenditures in total amount and
type offers a fruitful area for future research. Difficulties encountered in implementing the standard and how companies
and investors have reacted to it should prove interesting. Also,
the appropriateness of the selective capitalization of R&D in
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specific industries, such as the drug industry, merits investigation. Furthermore, the impact of SFAS No. 2 on small developing companies should be researched in depth. Although this article has dealt primarily with the financial reporting of R&D
expenditures, the tax aspects of this subject merit further research. For instance, to what extent is the United States performing R&D overseas due to the tax advantages of foreign
countries?
Accounting research into the feasibility and appropriateness of capitalization and amortization of advertising costs
clearly has implications for the financial accounting treatment
of R&D costs, especially since advertising costs are perhaps
more difficult to match with future revenue than are R&D costs.
The direct costing approach in which only variable R&D costs
would be capitalized and expensed over future time periods deserves further consideration. Given the historical controversy
regarding the financial accounting of R&D costs, accounting
researchers and policy makers should focus carefully on the impact of the current accounting rules and analyze alternative accounting treatments.
In conclusion, the current requirement [SFAS No. 2] of expensing R&D costs as incurred for financial statement purposes
is inappropriate. R&D costs are material in amount, benefit future time periods, and should more clearly be matched with
(charged to) the revenues they help generate. They also clearly
fit the FASB definition of an asset. It is likely that corporations'
fear of losing the R&D tax shelter and the loss of flexibility in
managing reported profits via the timing of R&D expenditures
are major obstacles to change in existing financial reporting
requirements. However, a change in the financial reporting of
these expenditures is in order.
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